Prothena (PRTA) Expected to Post Earnings on Thursday

Prothena (NASDAQ:PRTA) is projected to issue its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect Prothena to announce earnings of ($0.2271) per share and revenue of $9.58 million for the quarter. Parties can find conference call details on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:00 PM ET.

Prothena (NASDAQ:PRTA) last announced its earnings results on Thursday, August 6th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.07. The business had revenue of $1.01 million during the quarter, compared to analyst estimates of $0.42 million. Prothena had a negative return on equity of 16.45% and a negative net margin of 80.68%. On average, analysts expect Prothena to post $0.08 EPS for the current fiscal year and ($1.13) EPS for the next fiscal year.

Prothena Stock Performance

PRTA opened at $8.21 on Wednesday. The stock’s 50 day moving average price is $8.72 and its 200-day moving average price is $9.21. Prothena has a one year low of $7.73 and a one year high of $11.80. The stock has a market cap of $429.79 million, a price-to-earnings ratio of -9.77, a P/E/G ratio of 2.92 and a beta of -0.20.

Insider Buying and Selling at Prothena

In other news, major shareholder William P. Scully purchased 50,000 shares of the company’s stock in a transaction dated Friday, October 23rd. The shares were acquired at an average price of $8.07 per share, with a total value of $403,500.00. Following the transaction, the insider owned 1,187,000 shares of the company’s stock, valued at $9,579,090. This represents a 4.40% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In the last three months, insiders acquired 1,017,500 shares of company stock valued at $8,654,850. 10.40% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the company. Wall Street Zen cut Prothena from a “buy” rating to a “hold” rating in a report on Saturday, July 25th. Weiss Ratings lowered Prothena from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, October 29th. UBS Group reiterated a “buy” rating on shares of Prothena in a research report on Friday, July 24th. Finally, HC Wainwright reissued a “buy” rating and set a $30.00 target price on shares of Prothena in a research note on Friday, July 24th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $20.00.

About Prothena

Prothena Corporation plc (NASDAQ: PRTA) is a clinical-stage biotechnology company focused on discovering and developing novel medicines for serious neurodegenerative and rare peripheral diseases. Its research is centered on disease-causing proteins, including amyloid-beta, alpha-synuclein and transthyretin, with the goal of creating antibody-based therapies that address underlying disease mechanisms.

The company’s product pipeline has included birtamimab, an investigational antibody being developed for the treatment of AL amyloidosis, and prasinezumab, an investigational alpha-synuclein antibody being developed in collaboration with Roche for certain forms of Parkinson’s disease.